
Pfizer Taps Blackstone for $1.5B Obesity Drug
Pfizer ($PFE) struck a non-dilutive funding deal with Blackstone Life Sciences, which will provide up to $1.5 billion through 2028 to cover clinical costs for berobenatide, Pfizer's monthly GLP-1 obesity candidate. Unlike a typical equity raise, Blackstone gets no ownership stake in the drug, only milestone-based payments, while Pfizer keeps full operational control of the program. The structure lets Pfizer fund its obesity pipeline against entrenched rivals Novo Nordisk and Eli Lilly without issuing new shares.